One quick exercise you can do - MXC today annouced they just hit 400 patients. AGH as you said has likely 5 times that currently (we will know with certainty soon).
Their MC is roughly $57m, AGH currently is $139 - shouldn't we be, based purely on a comparable multiple basis - closer to $250m?
This doesn't even take into consideration premiums that should be applied for our market leading position, 20,000 patient trial in UK and expansion growth potential in Portugal and France.
